期刊文献+

维生素D水平与卵巢癌患者生存状态的关系研究

The Relationship between Vitamin D Levels and the Survival Status of Patients with Ovarian Cancer
下载PDF
导出
摘要 目的:探讨维生素D水平与卵巢癌患者生存状态的关系。方法:纳入2009年8月至2011年1月期间收治的168例卵巢癌患者,随访5年,利用Log rank检验和方差分析等比较不同血清25(OH)D水平患者的无进展生存期(率)、5年总生存期(率)和Karnofsky评分。结果:不同血清25(OH)D水平患者的中位无进展生存期和5年无进展生存率比较差异无统计学意义(χ2=2.298,logrank P=0.513);而不同血清25(OH)D水平患者的中位生存期和5年总生存率比较差异有统计学意义(χ2=12.342,log-rank P=0.006),25(OH)D为25.0~49.9 nmo L/L水平患者的中位生存期最高,50.0~74.9 nmo L/L者5年总生存率最高;不同血清25(OH)D水平患者的Karnofsky评分差异无统计学意义(P均>0.05)。结论:维生素D水平与卵巢癌患者的5年总生存率相关,血清25(OH)D浓度为25.0~74.9nmo L/L者生存状态更好。 Objective:To explore the relationship between vitamin D levels and the survival status of patients with ovarian cancer.Method:Total 168 patients with ovarian cancer were included during August 2009 to January 2011,then 5 years follow up was conducted,Log rank test and variance analysis were used to compare the progression free survival(rate),5-year overall survival(rate),and Karnofsky score among patients with different serum 25(OH)D levels.Results:The median progression-free survival and 5-year progression-free survival were not significantly difference among patients with different serum 25(OH)D levels(χ2=2.298,log-rank P=0.513);the median overall survival and 5-year overall survival were significantly difference among patients with different serum 25(OH)D levels(χ2=12.342,log-rank P=0.006),and patients with serum levels of 25.0~49.9 nmoL/L had longest median overall survival,while 50.0~74.9 nmoL/L had highest overall survival rate;Karnofsky scores was also no significantly difference among patients with different serum 25(OH)D levels(P>0.05).Conclusion:The vitamin D levels are associated with the 5 year total survival rate in patients with ovarian cancer,and the survival status of 25.0~74.9 nmoL/L in serum 25(OH)D was better.
作者 伍雪梅 蒋红微 李彬 彭小凤 WU Xuemei(Shenzhen Maternal and Child Health Hospital,Guangdong Shenzhen 518000,China)
出处 《河北医学》 CAS 2018年第4期667-671,共5页 Hebei Medicine
关键词 维生素D 卵巢癌 生存状态 Vitamin D Ovarian cancer Survival status
  • 相关文献

参考文献5

二级参考文献91

  • 1卢航青,郑杰.全反式维甲酸和1α,25二羟维生素D_3对肝癌细胞HepG2生长的协同抑制作用[J].癌症,2006,25(12):1470-1476. 被引量:12
  • 2Baeke F, Takiishi T, Kort H, et al. Vitamin D :modulator of the im- mune system[J]. Curt Opin Pharmacol, 2010, 10(4) : 482-496.
  • 3Holick ME. Vitamin D deficiency [ J ]. N Engl J Med, 2007, 357:266-281.
  • 4Haussler MR, Jurutka P, Mizwicki M, et al. VotaminD receptor (VDR) -mediated actions of 1 α, 25 ( OH ) Vitamin D3 : Genomic and non-genomic mechanisms [ J ]. Best Pract Res Clin Endocri- nol Metab, 2011, 25(4) :543-559.
  • 5Wang TT, Dabbas B, Laperriere D, et al. Piret and indirect in- duction by 1,25 dihydroxyvitamin D3 of the NOD2/CARD 15-de- fensin beta2 innate immune Pathway defective in Crohn disease [J]. J Biol Chem,2010,285(4):2227-2231.
  • 6Khoo AL, Chai LYA, Koeren HJPM, et al. Vitamin D3 down- regulates Proinflammatory eytokine response to Myeobaeterium tu- berculosis through Pattern recognition releptors while inducing protective cathelicidin prodnction [ J ]. Cytokine, 2011,55 ( 2 ) : 294 -300.
  • 7Gynther P, Toropainen S, Matilainen JM, et al. Mechanism of 1 α, 25-dihydroxyvitanin D3-dependent repression of intedeukin- 12B[J]. BBA, 2011,1813(5):810-818.
  • 8Peelen E, Knippenberg S, Muris AH, et al. Effects of vitamin D on the peripheral adaptive immune system: A review [ J ]. Auto- immun Rev, 2011,10(12) :733-743.
  • 9Borges MC, Martini LA, Rogero MM, et al. Current perspertives on Vitamin D, immune system, and chronic diseases [ J ]. Nutri- tion, 2011, 27(4) :399-404.
  • 10Correale J, Srraelit MC, Gaitan MI, et al. Vitamin D-mediated immune regulation in Multiple Sclerosis[J]. J Neurol Sci, 2011, 311 (1-2) :23-31.

共引文献98

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部